{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T18:23:26Z","timestamp":1794075806467,"version":"4.8.0"},"reference-count":151,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ejca.2026.116711","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T03:56:50Z","timestamp":1774929410000},"page":"116711","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["From prediction to precision: Biomarker discovery and predictive modeling for personalized immune checkpoint blockade therapy"],"prefix":"10.1016","volume":"239","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9985-0753","authenticated-orcid":false,"given":"Steven C.M.A.","family":"Wijnen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Dimitriadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lodewyk F.A.","family":"Wessels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7945-5846","authenticated-orcid":false,"given":"Christian U.","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116711_bib1","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2026.116711_bib2","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.eururo.2017.02.010","article-title":"CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma","volume":"72","author":"Escudier","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2026.116711_bib3","doi-asserted-by":"crossref","first-page":"274.e1","DOI":"10.1016\/j.clgc.2020.10.003","article-title":"Real-world data of nivolumab for patients with advanced renal cell carcinoma in the netherlands: an analysis of toxicity, efficacy, and predictive markers","volume":"19","author":"Verhaart","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ejca.2026.116711_bib4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2026.116711_bib5","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non\u2013small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2026.116711_bib6","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.116711_bib7","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus Ipilimumab in advanced non\u2013small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2026.116711_bib8","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1038\/s41591-024-03249-3","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial","volume":"30","author":"Nederlof","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2026.116711_bib9","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.116711_bib10","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116711_bib11","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jamaoncol.2018.4514","article-title":"Survival outcomes in patients with previously untreated braf wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial","volume":"5","author":"Ascierto","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2026.116711_bib12","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage iii melanoma","author":"Blank","year":"2024","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2026.116711_bib13","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.116711_bib14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.semcancer.2021.03.036","article-title":"Predictive biomarkers for response to immune checkpoint inhibition","volume":"79","author":"Shum","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.ejca.2026.116711_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-26472-9","article-title":"Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma","volume":"12","author":"Vos","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2026.116711_bib16","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2026.116711_bib17","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamaoncol.2020.0237","article-title":"Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non\u2013small cell lung cancer: the mystic phase 3 randomized clinical trial","volume":"6","author":"Rizvi","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2026.116711_bib18","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1158\/2159-8290.CD-20-1209","article-title":"Development of immunotherapy combination strategies in cancer","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2026.116711_bib19","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.3390\/ijms23052847","article-title":"Challenges of the immunotherapy: perspectives and limitations of the immune checkpoint inhibitor treatment","volume":"23","author":"Dobosz","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejca.2026.116711_bib20","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116711_bib21","doi-asserted-by":"crossref","first-page":"4946","DOI":"10.1038\/s41467-020-18742-9","article-title":"Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy","volume":"11","author":"Jing","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2026.116711_bib22","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1001\/jamaoncol.2019.5570","article-title":"Association between immune-related adverse events and recurrence-free survival among patients with stage iii melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial","volume":"6","author":"Eggermont","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2026.116711_bib23","doi-asserted-by":"crossref","first-page":"7449","DOI":"10.1038\/s41598-019-43525-8","article-title":"Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma","volume":"9","author":"Harder","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2026.116711_bib24","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jamaoncol.2021.6818","article-title":"Early readout on overall survival of patients with melanoma treated with immunotherapy using a novel imaging analysis","volume":"8","author":"Dercle","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2026.116711_bib25","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3\u2013related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejca.2026.116711_bib26","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.ccell.2024.08.007","article-title":"Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells","volume":"42","author":"Wang","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2026.116711_bib27","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3389\/fimmu.2017.00386","article-title":"Association of CTLA-4 gene variants with response to therapy and long-term survival in metastatic melanoma patients treated with ipilimumab: an italian melanoma intergroup study","volume":"8","author":"Queirolo","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejca.2026.116711_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.796647","article-title":"A pan-cancer analysis of predictive methylation signatures of response to cancer immunotherapy","volume":"12","author":"Xu","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejca.2026.116711_bib29","article-title":"Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review","author":"Prelaj","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116711_bib30","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.ccell.2022.09.012","article-title":"Artificial intelligence for multimodal data integration in oncology","volume":"40","author":"Lipkova","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2026.116711_bib31","article-title":"Elucidation of the application of blood test biomarkers to predict immune-related adverse events in atezolizumab-treated nsclc patients using machine learning methods","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejca.2026.116711_bib32","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s43018-023-00572-5","article-title":"Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer","volume":"4","author":"Sung","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.ejca.2026.116711_bib33","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2026.116711_bib34","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/s41591-020-01211-7","article-title":"Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma","volume":"27","author":"Rozeman","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2026.116711_bib35","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","article-title":"Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial","volume":"28","author":"Reijers","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2026.116711_bib36","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","article-title":"Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma","volume":"25","author":"Cloughesy","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2026.116711_bib37","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2026.116711_bib38","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/s41571-023-00760-3","article-title":"Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma","volume":"20","author":"Lucas","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116711_bib39","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1158\/2159-8290.CD-23-0352","article-title":"Biomarker-Driven Personalization of Neoadjuvant Immunotherapy in Melanoma","volume":"13","author":"Hoeijmakers","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2026.116711_bib40","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.lungcan.2017.08.005","article-title":"PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review","volume":"112","author":"Brody","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2026.116711_bib41","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1038\/s41467-021-24112-w","article-title":"Molecular determinants of response to PD-L1 blockade across tumor types","volume":"12","author":"Banchereau","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2026.116711_bib42","article-title":"FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2026.116711_bib43","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.116711_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104633","article-title":"Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1\/PD-L1 immunotherapy in non-small cell lung cancer","volume":"92","author":"Ghiringhelli","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejca.2026.116711_bib45","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231186027","article-title":"The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition","volume":"15","author":"Kreidieh","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejca.2026.116711_bib46","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116711_bib47","doi-asserted-by":"crossref","first-page":"CT002","DOI":"10.1158\/1538-7445.AM2023-CT002","article-title":"Abstract CT002: KEYMAKER-U02 substudy 02C: neoadjuvant pembrolizumab (pembro) + vibostolimab (vibo) or gebasaxturev (geba) or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma","volume":"83","author":"Dummer","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2026.116711_bib48","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 comes of age as an inhibitory receptor","volume":"20","author":"Wolf","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ejca.2026.116711_bib49","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41586-022-05368-8","article-title":"Neoadjuvant relatlimab and nivolumab in resectable melanoma","volume":"611","author":"Amaria","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2026.116711_bib50","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000957","article-title":"TIGIT in cancer immunotherapy","volume":"8","author":"Chauvin","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2026.116711_bib51","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2026.116711_bib52","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ejca.2026.116711_bib53","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The challenges of tumor mutational burden as an immunotherapy biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2026.116711_bib54","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2026.116711_bib55","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1470-2045(17)30516-8","article-title":"Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis","volume":"18","author":"Turajlic","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116711_bib56","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA approval summary: pembrolizumab for the treatment of tumor mutational burden\u2013high solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116711_bib57","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant immunotherapy in locally advanced mismatch repair\u2013deficient colon cancer","volume":"390","author":"Chalabi","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116711_bib58","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2026.116711_bib59","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","article-title":"Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition","volume":"184","author":"Litchfield","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2026.116711_bib60","article-title":"Integrative tumor and immune cell multi-omic analyses predict response to immune checkpoint blockade in melanoma","volume":"1","author":"Anagnostou","year":"2020","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.ejca.2026.116711_bib61","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cell.2020.09.015","article-title":"Key Parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction","volume":"183","author":"Wells","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2026.116711_bib62","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1016\/j.immuni.2023.09.002","article-title":"Machine learning methods and harmonized datasets improve immunogenic neoantigen prediction","volume":"56","author":"M\u00fcller","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.ejca.2026.116711_bib63","article-title":"NeoPrecis: enhancing immunotherapy response prediction through integration of qualified immunogenicity and clonality-aware neoantigen landscapes","author":"Lee","year":"2025","journal-title":"Preprint"},{"key":"10.1016\/j.ejca.2026.116711_bib64","doi-asserted-by":"crossref","DOI":"10.1002\/pro.4708","article-title":"Shining a light on the dark proteome: Non-canonical open reading frames and their encoded miniproteins as a new frontier in cancer biology","volume":"32","author":"Posner","year":"2023","journal-title":"Protein Sci Publ Protein Soc"},{"key":"10.1016\/j.ejca.2026.116711_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102662","article-title":"Review \u2013 The impact of pharmacogenetics on the outcome of immune checkpoint inhibitors","volume":"122","author":"De Joode","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2026.116711_bib66","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ccell.2018.02.010","article-title":"Fc effector function contributes to the activity of human anti-CTLA-4 antibodies","volume":"33","author":"Arce Vargas","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2026.116711_bib67","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20221952","article-title":"IFN-\u03b3 signature enables selection of neoadjuvant treatment in patients with stage III melanoma","volume":"220","author":"Reijers","year":"2023","journal-title":"J Exp Med"},{"key":"10.1016\/j.ejca.2026.116711_bib68","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2026.116711_bib69","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1158\/2326-6066.CIR-22-0494","article-title":"Inhibitor of apoptosis proteins antagonist induces t-cell proliferation after cross-presentation by dendritic cells","volume":"11","author":"Hoefsmit","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ejca.2026.116711_bib70","doi-asserted-by":"crossref","first-page":"eabj9779","DOI":"10.1126\/scitranslmed.abj9779","article-title":"Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors","volume":"14","author":"Kaptein","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ejca.2026.116711_bib71","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-00494","article-title":"Long-term survival and biomarker analysis evaluating neoadjuvant plus adjuvant relatlimab (anti-lag3) and nivolumab (anti-pd1) in patients with resectable melanoma","author":"Burton","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116711_bib72","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1038\/s41467-020-15726-7","article-title":"Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition","volume":"11","author":"Lee","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2026.116711_bib73","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2026.116711_bib74","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41591-019-0595-z","article-title":"A clonal expression biomarker associates with lung cancer mortality","volume":"25","author":"Biswas","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2026.116711_bib75","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.mam.2017.07.002","article-title":"Identifying cell populations with scRNASeq","volume":"59","author":"Andrews","year":"2018","journal-title":"Mol Asp Med"},{"key":"10.1016\/j.ejca.2026.116711_bib76","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nbt.4096","article-title":"Integrating single-cell transcriptomic data across different conditions, technologies, and species","volume":"36","author":"Butler","year":"2018","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.ejca.2026.116711_bib77","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/s41467-022-28803-w","article-title":"Fully-automated and ultra-fast cell-type identification using specific marker combinations from single-cell transcriptomic data","volume":"13","author":"Ianevski","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2026.116711_bib78","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3390\/genes10070531","article-title":"SCINA: semi-supervised analysis of single cells in silico","volume":"10","author":"Zhang","year":"2019","journal-title":"Genes"},{"key":"10.1016\/j.ejca.2026.116711_bib79","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13059-021-02281-7","article-title":"scSorter: assigning cells to known cell types according to marker genes","volume":"22","author":"Guo","year":"2021","journal-title":"Genome Biol"},{"key":"10.1016\/j.ejca.2026.116711_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.100882","article-title":"scCATCH: automatic annotation on cell types of clusters from single-cell rna sequencing data","volume":"23","author":"Shao","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.ejca.2026.116711_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104207","article-title":"Pan-cancer landscape of T-cell exhaustion heterogeneity within the tumor microenvironment revealed a progressive roadmap of hierarchical dysfunction associated with prognosis and therapeutic efficacy","volume":"83","author":"Zhang","year":"2022","journal-title":"eBioMedicine"},{"key":"10.1016\/j.ejca.2026.116711_bib82","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","article-title":"Clonal replacement of tumor-specific T cells following PD-1 blockade","volume":"25","author":"Yost","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2026.116711_bib83","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.ccell.2021.09.010","article-title":"Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer","volume":"39","author":"Zhang","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2026.116711_bib84","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.ccell.2021.03.007","article-title":"Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy","volume":"39","author":"Krishna","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2026.116711_bib85","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ccell.2025.02.026","article-title":"Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies","volume":"43","author":"Li","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2026.116711_bib86","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.ccell.2022.08.005","article-title":"NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer","volume":"40","author":"Salom\u00e9","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2026.116711_bib87","article-title":"An immunotherapy response prediction model derived from proliferative CD4+ T cells and antigen-presenting monocytes in ccRCC","volume":"13","author":"Zheng","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejca.2026.116711_bib88","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ccell.2021.02.015","article-title":"Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma","volume":"39","author":"Bi","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2026.116711_bib89","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13073-022-01075-1","article-title":"An introduction to spatial transcriptomics for biomedical research","volume":"14","author":"Williams","year":"2022","journal-title":"Genome Med"},{"key":"10.1016\/j.ejca.2026.116711_bib90","doi-asserted-by":"crossref","first-page":"8353","DOI":"10.1038\/s41467-023-43458-x","article-title":"High resolution mapping of the tumor microenvironment using integrated single-cell, spatial and in situ analysis","volume":"14","author":"Janesick","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2026.116711_bib91","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.3390\/cancers13174456","article-title":"Best practices for spatial profiling for breast cancer research with the geomx\u00ae digital spatial profiler","volume":"13","author":"Bergholtz","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2026.116711_bib92","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12864-025-11235-3","article-title":"A practical guide for choosing an optimal spatial transcriptomics technology from seven major commercially available options","volume":"26","author":"Lim","year":"2025","journal-title":"BMC Genom"},{"key":"10.1016\/j.ejca.2026.116711_bib93","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12864-025-11235-3","article-title":"A practical guide for choosing an optimal spatial transcriptomics technology from seven major commercially available options","volume":"26","author":"Lim","year":"2025","journal-title":"BMC Genom"},{"key":"10.1016\/j.ejca.2026.116711_bib94","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1158\/2159-8290.CD-23-1300","article-title":"Spatially segregated macrophage populations predict distinct outcomes in colon cancer","volume":"14","author":"Matusiak","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2026.116711_bib95","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.cell.2023.11.037","article-title":"A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma","volume":"187","author":"Pozniak","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2026.116711_bib96","article-title":"A comprehensive single-cell breast tumor atlas defines epithelial and immune heterogeneity and interactions predicting anti-PD-1 therapy response","volume":"5","author":"Xu","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.ejca.2026.116711_bib97","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1158\/0008-5472.CAN-22-3034","article-title":"Mesenchymal-like tumor cells and myofibroblastic cancer-associated fibroblasts are associated with progression and immunotherapy response of clear cell renal cell carcinoma","volume":"83","author":"Davidson","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2026.116711_bib98","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12943-023-01731-z","article-title":"Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1\/PD-L1 immunotherapy for solid cancers","volume":"22","author":"Pei","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ejca.2026.116711_bib99","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1158\/2159-8290.CD-19-1384","article-title":"Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer","volume":"10","author":"Kieffer","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2026.116711_bib100","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1158\/1078-0432.CCR-21-3570","article-title":"Immunostimulatory cancer-associated fibroblast subpopulations can predict immunotherapy response in head and neck cancer","volume":"28","author":"Obradovic","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116711_bib101","doi-asserted-by":"crossref","first-page":"6619","DOI":"10.1038\/s41467-022-34395-2","article-title":"Pan-cancer single-cell analysis reveals the heterogeneity and plasticity of cancer-associated fibroblasts in the tumor microenvironment","volume":"13","author":"Luo","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2026.116711_bib102","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1158\/0008-5472.CAN-23-1448","article-title":"Spatial and single-cell transcriptomics reveal a cancer-associated fibroblast subset in HNSCC that restricts infiltration and antitumor activity of CD8+ T cells","volume":"84","author":"Li","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2026.116711_bib103","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12943-023-01876-x","article-title":"Pan-cancer spatially resolved single-cell analysis reveals the crosstalk between cancer-associated fibroblasts and tumor microenvironment","volume":"22","author":"Ma","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ejca.2026.116711_bib104","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","article-title":"Tertiary lymphoid structures in the era of cancer immunotherapy","volume":"19","author":"Saut\u00e8s-Fridman","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2026.116711_bib105","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2026.116711_bib106","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.immuni.2022.02.001","article-title":"Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer","volume":"55","author":"Meylan","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.ejca.2026.116711_bib107","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ccell.2022.01.002","article-title":"Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy","volume":"40","author":"Asrir","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2026.116711_bib108","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12935-025-04161-7","article-title":"Single-cell spatial analysis identifies ID1-high endothelial cells in tertiary lymphoid structures as predictors of durable response to immunotherapy in non-small cell lung cancer","volume":"26","author":"Matsumoto","year":"2026","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.ejca.2026.116711_bib109","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1038\/s41467-022-31535-6","article-title":"Network-based machine learning approach to predict immunotherapy response in cancer patients","volume":"13","author":"Kong","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2026.116711_bib110","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","article-title":"Conserved pan-cancer microenvironment subtypes predict response to immunotherapy","volume":"39","author":"Bagaev","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2026.116711_bib111","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","article-title":"Regression shrinkage and selection via the lasso","volume":"58","author":"Tibshirani","year":"1996","journal-title":"J R Stat Soc Ser B Method"},{"key":"10.1016\/j.ejca.2026.116711_bib112","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejca.2020.09.015","article-title":"Machine learning reveals a PD-L1\u2013independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context","volume":"140","author":"Wiesweg","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116711_bib113","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.808378","article-title":"A somatic mutation signature predicts the best overall response to anti-programmed cell death protein-1 treatment in epidermal growth factor receptor\/anaplastic lymphoma kinase-negative non-squamous non-small cell lung cancer","volume":"9","author":"Peng","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.ejca.2026.116711_bib114","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41698-021-00184-1","article-title":"Models that combine transcriptomic with spatial protein information exceed the predictive value for either single modality","volume":"5","author":"Vathiotis","year":"2021","journal-title":"Npj Precis Oncol"},{"key":"10.1016\/j.ejca.2026.116711_bib115","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.960459","article-title":"Deep learning to estimate durable clinical benefit and prognosis from patients with non-small cell lung cancer treated with PD-1\/PD-L1 blockade","volume":"13","author":"Peng","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejca.2026.116711_bib116","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000631","article-title":"Prediction of immune checkpoint inhibition with immune oncology-related gene expression in gastrointestinal cancer using a machine learning classifier","volume":"8","author":"Lu","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2026.116711_bib117","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/s41467-025-56462-0","article-title":"Predicting immunotherapy response of advanced bladder cancer through a meta-analysis of six independent cohorts","volume":"16","author":"Boll","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2026.116711_bib118","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41568-022-00513-x","article-title":"Targeting the gut microbiota for cancer therapy","volume":"22","author":"Fernandes","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2026.116711_bib119","doi-asserted-by":"crossref","first-page":"876","DOI":"10.18632\/oncotarget.28252","article-title":"Predicting cancer immunotherapy response from gut microbiomes using machine learning models","volume":"13","author":"Liang","year":"2022","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2026.116711_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.112162","article-title":"Enriched pathways in gut microbiome predict response to immune checkpoint inhibitor treatment across demographic regions and various cancer types","volume":"28","author":"Cai","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.ejca.2026.116711_bib121","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13073-022-01050-w","article-title":"Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response","volume":"14","author":"Zhang","year":"2022","journal-title":"Genome Med"},{"key":"10.1016\/j.ejca.2026.116711_bib122","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s43018-024-00743-y","article-title":"Sarcoma microenvironment cell states and ecosystems are associated with prognosis and predict response to immunotherapy","volume":"5","author":"Subramanian","year":"2024","journal-title":"Nat Cancer"},{"key":"10.1016\/j.ejca.2026.116711_bib123","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1158\/2326-6066.CIR-23-0873","article-title":"Machine learning links t-cell function and spatial localization to neoadjuvant immunotherapy and clinical outcome in pancreatic cancer","volume":"12","author":"Blise","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ejca.2026.116711_bib124","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41591-020-0860-1","article-title":"High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade","volume":"26","author":"Yuen","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2026.116711_bib125","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13046-024-02969-1","article-title":"Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade","volume":"43","author":"Tsai","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116711_bib126","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41467-021-20935-9","article-title":"Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors","volume":"12","author":"Valero","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2026.116711_bib127","article-title":"The role of cytokines in predicting the response and adverse events related to immune checkpoint inhibitors","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejca.2026.116711_bib128","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13046-024-03074-z","article-title":"Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies","volume":"43","author":"Pitts","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116711_bib129","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1093\/annonc\/mdz196","article-title":"Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?","volume":"30","author":"Hofman","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116711_bib130","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/s41591-018-0134-3","article-title":"Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab","volume":"24","author":"Gandara","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2026.116711_bib131","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41587-021-01070-8","article-title":"Improved prediction of immune checkpoint blockade efficacy across multiple cancer types","volume":"40","author":"Chowell","year":"2022","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.ejca.2026.116711_bib132","doi-asserted-by":"crossref","DOI":"10.1038\/s43018-024-00772-7","article-title":"LORIS robustly predicts patient outcomes with immune checkpoint blockade therapy using common clinical, pathologic and genomic features","author":"Chang","year":"2024","journal-title":"Nat Cancer"},{"key":"10.1016\/j.ejca.2026.116711_bib133","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejca.2021.05.019","article-title":"Clinical decision support algorithm based on machine learning to assess the clinical response to anti\u2013programmed death-1 therapy in patients with non\u2013small-cell lung cancer","volume":"153","author":"Ahn","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116711_bib134","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.585311","article-title":"Biomarkers of checkpoint inhibitor induced immune-related adverse events\u2014a comprehensive review","volume":"10","author":"Hommes","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2026.116711_bib135","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1001\/jamaoncol.2022.5041","article-title":"Association of immune-related adverse event management with survival in patients with advanced melanoma","volume":"8","author":"Van Not","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2026.116711_bib136","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2026.116711_bib137","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors","volume":"13","author":"Chennamadhavuni","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejca.2026.116711_bib138","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1038\/s41591-022-02095-5","article-title":"IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma","volume":"28","author":"Taylor","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2026.116711_bib139","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1038\/s41591-022-02094-6","article-title":"Germline variants associated with toxicity to immune checkpoint blockade","volume":"28","author":"Groha","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2026.116711_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105575","article-title":"Profiling autoantibodies at baseline and during immune checkpoint inhibitor therapy of renal cell carcinoma patients\u2014exploratory results from TITAN-RCC","volume":"10","author":"Fritzsch","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2026.116711_bib141","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41591-020-0829-0","article-title":"Learning from clinical trials of neoadjuvant checkpoint blockade","volume":"26","author":"Versluis","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2026.116711_bib142","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/s43018-025-00990-7","article-title":"The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types","volume":"6","author":"Awada","year":"2025","journal-title":"Nat Cancer"},{"key":"10.1016\/j.ejca.2026.116711_bib143","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1200\/OP.22.00226","article-title":"Immunotherapy in the management of esophagogastric cancer: a practical review","volume":"19","author":"Patruni","year":"2023","journal-title":"JCO Oncol Pr"},{"key":"10.1016\/j.ejca.2026.116711_bib144","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","article-title":"ESMO clinical practice guideline interim update on first-line therapy in advanced urothelial carcinoma","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116711_bib145","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1200\/JCO-25-00494","article-title":"Long-term survival and biomarker analysis evaluating neoadjuvant plus adjuvant relatlimab (anti-lag3) and nivolumab (anti-pd1) in patients with resectable melanoma","volume":"43","author":"Burton","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116711_bib146","article-title":"Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies","author":"Li","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2026.116711_bib147","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13073-023-01164-9","article-title":"Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing","volume":"15","author":"Hu","year":"2023","journal-title":"Genome Med"},{"key":"10.1016\/j.ejca.2026.116711_bib148","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00262-025-04094-0","article-title":"Dissecting response to neoadjuvant immunotherapy-treated melanoma using cancer-immunity cycle-associated signatures","volume":"74","author":"Wijnen","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejca.2026.116711_bib149","article-title":"Lessons from neoadjuvant immunotherapy in melanoma: understanding antitumour immunity and tumour escape","author":"Fallarino","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ejca.2026.116711_bib150","doi-asserted-by":"crossref","unstructured":"Blank, C. et al. Long-term survival after neoadjuvant low-dose ipilimumab plus high-dose nivolumab in resectable stage III melanoma: the 5-year survival-update and biomarker analysis from the PRADO-trial. Preprint at \u3008https:\/\/doi.org\/10.21203\/rs.3.rs-7090131\/v1\u3009 (2025).","DOI":"10.21203\/rs.3.rs-7090131\/v1"},{"key":"10.1016\/j.ejca.2026.116711_bib151","doi-asserted-by":"crossref","first-page":"S995","DOI":"10.1016\/j.annonc.2025.08.2311","article-title":"1683TiP OMIT trial: omitting therapeutic lymph node dissection in patients with stage IIIB\/C melanoma and major pathological response in the index lymph node after neoadjuvant immunotherapy","volume":"36","author":"Schurink","year":"2025","journal-title":"Ann Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926004910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926004910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:23:57Z","timestamp":1794072237000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926004910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":151,"alternative-id":["S0959804926004910"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116711","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From prediction to precision: Biomarker discovery and predictive modeling for personalized immune checkpoint blockade therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116711","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116711"}}